Abbreviations and References - Handbook 2021 Workshop
In this guide
In this guideOn this page
Skip the menu of subheadings on this page.Abbreviations
|
ADME |
Absorption, Distribution, Metabolism and Excretion |
|
AOP |
Adverse Outcome Pathway |
|
ATSDR |
Agency for Toxic Substances and Disease Registry |
|
BMDL |
Benchmark Dose Level |
|
COT |
Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment |
|
DDI |
Drug-drug interaction |
|
EFPIA |
European Federation of Pharmaceutical Industries and Associations |
|
EFSA |
European Food Safety Authority |
|
EMA |
European Medicines Agency |
|
EURL-ECVAM |
European Union Reference Laboratory for Alternatives to Animal Testing |
|
FSA |
Food Standards Agency |
|
HBM |
Human Biomonitoring |
|
HESI |
Health and Environmental Sciences Institute |
|
Httk |
High-Throughput Toxicokinetics |
|
ICF |
IndusChemFate |
|
ICH |
International Council for Harmonisation |
|
ILSI |
International Life Sciences Institute |
|
IMED |
Innovative Medicines |
|
IPCS |
International Programme on Chemical Safety |
|
ISI |
The Institute for Scientific Information |
|
JECFA |
Joint Food and Agriculture Organisation/World Health Expert Committee on Food Additives |
|
JMPR |
Joint Food and Agriculture Organisation/World Health Expert Committee on Pesticide Residues |
|
LJMU |
Liverpool John Moores University |
|
MoA |
Mode of Action |
|
NAMs |
New Approach Methodologies |
|
NOAEL |
No-observed-adverse-effect-level |
|
OECD |
Organisation for Economic Cooperation and Development OSHA |
|
OECD |
Organisation for Economic Cooperation and Development OSHA |
|
PBPK |
Physiologically based Pharmacokinetic Modelling |
|
PFOA |
Perfluorooctanoic acid |
|
(Q)SAR |
(Quantitative-) Structure Activity Relationship SERD |
|
TD |
Toxicodynamic |
|
TK |
Toxicokinetic |
|
US EPA |
United States Environmental Protection Agency US FDA |
|
TD |
Toxicodynamic |
|
WHO |
World Health Organisation |
References
Andersen, M. E., Clewell III, H. J., Gargas, M. L., Smith, F. A. and Reitz, R. H. (1987) Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicology and Applied Pharmacology 87(2), pp. 185-205.
Bossier, H., Chau, J., Ndour, C., Varewyck, M., Verbeke, T. and Vergucht, S. (2020) A Web-based open source tool for Toxicokinetic and Toxicodynamic modelling. EFSA Supporting Publication: EN-1926. Available at: A Web‐based open source tool for Toxicokinetic and Toxicodynamic modelling | EFSA (europa.eu). Accessed: 17/11/2020.
IPCS. (2005) Principles of characterizing and applying human exposure models. Geneva, World Health Organisation, International Programme on Chemical Safety. Harmonisation Project Document No. 3; pp.67. Available at: Principles of characterizing and applying human exposure models (who.int) Accessed: 28/10/2020.
OECD. (2005) Guidance document on the validation and international acceptance of new or updated test methods for hazard assessment. OECD Series on Testing and Assessment Number 34. OECD Guidance Document 34: Validation and International Acceptance of New or Updated Internationally Acceptable Test Methods for Hazard Assessment (nih.gov) Accessed: 17/11/2020.
Paini, A., Leonard, J. A., Kliment, T., Tan, Y-M. and Worth, A. (2017) Investigating the state of physiologically based kinetic modelling practices and challenges associated with gaining regulatory acceptance of model applications. Regulatory Toxicology and Pharmacology 90, pp. 104-115.
Parish, S. T., Aschner, M., Casey, W., Corvaro, M., Embry, M. R., Fitzpatrick, S., Kidd, D., Kleinstreuer, N. C., Lima, B, S., Settivari, R. S., Wolf, D. C., Yamazaki, D. and Boobis, A. (2020) An evaluation framework for new approach methodologies (NAMs) for human health safety assessment. Regulatory Toxicology and Pharmacology 111, 104592.
Pletz, J., Blakeman, S., Paini, A., Parissis, N., Worth, A., Andersson, A-M., Frederiksen, H., Sakhi, A. K., Thomsen, C. and Bopp, S. K. (2020) Physiologically based kinetic (PBK) modelling and human biomonitoring data for mixture risk assessment. Environment International 143, 105978.
Rietjens, I. M. C. M., Louisse, J. and Punt, A. (2011) Tutorial on physiologically based kinetic modelling in molecular nutrition and food research. Molecular Nutrition and Food Research 55(6), pp. 941-956.
Sager, J. E., Yu, J., Raguneneau-Majlessi, I. and Isoherran, N. (2015) Physiologically based pharmacokinetic (PBPK) modelling and simulation approaches: A systematic review of published models, applications, and model verification. Drug Metabolism and Disposition 34; pp. 1823-1837.
Tan, Y-M., Chan, M., Chukwudebe, A., Domoradzki, J., Fisher, J., Hack, C. E., Hinderliter, P., Hirasawa, K., Leonard, J., Lumen, A., Paini, A., Qian, H., Ruiz, P., Wambaugh, J., Zhang, F. and Embry. M. (2020) PBPK Model reporting template for chemical risk assessment applications. Regulatory Toxicology and Pharmacology 115, 104691.
Teorell, T. (1937) Kinetics of distribution of substances administered to the body. I & II. Archives internationales de pharmacodynamie et de therapie 57, pp. 205-240. ISSN 0003-9780.
US EPA. (2006) Approaches for the Application of Physiologically Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment (Final Report). U.S. Environmental Protection Agency, Washington, D.C., EPA/600/R-05/043F, 2006: Approaches For the Application of Physiologically Based Pharmacokinetic (PBPK) Models and Supporting Data In Risk Assessment (Final Report) | Risk Assessment Portal | US EPA Accessed: 28/10/2020.
WHO. (2010) Guidance on principles of characterizing and applying PBPK models in risk assessment: Characterization and application of physiologically based pharmacokinetic models in risk assessment (who.int) Accessed: 26/10/2020.